# Tracking Tau with In Vivo Braak Staging: Longitudinal Analysis of Tau Pathology and Functional Sequelae in Cognitively Healthy Older Adults

> **NIH NIH F32** · UNIVERSITY OF CALIFORNIA BERKELEY · 2020 · $5,621

## Abstract

Project Summary
Interventions designed to delay or prevent Alzheimer's disease (AD) are more likely to be effective if delivered
early in the course of the disease before clinical symptoms emerge. To identify individuals who are in the pre-
symptomatic or preclinical phase of AD the processes underlying early pathogenesis must be better
understood. Recently developed tau-specific positron emission tomography (PET) tracers are allowing
researchers to shed light on this critical neuropathology, which previously could only be examined post-mortem
or by proxy measures from a spinal tap. Braak staging, a framework for staging tau pathology in post-mortem
tissue based on density and topology of tau, may now be used to stage tau pathology in vivo. The current
proposal is designed to elucidate the temporal dynamics of AD pathology, especially tau, and associated
functional connectivity changes in cognitively healthy older adults. Specifically, longitudinal PET imaging of
both beta-amyloid and tau along with task-free functional MRI will be used to 1) characterize the extent and
spread of tau pathology using in vivo Braak staging, 2) examine the effect of tau pathology in Braak regions on
local functional coherence and 3) determine how tau pathology in medial temporal lobe (MTL) affects
functional connectivity to the retrosplenial cortex, which is anatomically connected (mono-synaptic) to MTL and
essential to normal memory function. The relationship of tau pathology, functional connectivity changes and
early changes in memory function will also be explored. The progression and severity of tau pathology are
associated with disease severity (cognition) across the mild cognitive impairment (MCI)-dementia spectrum. It
is critical, therefore, to elucidate the temporal dynamics of tau progression in aging and to examine possible
mechanisms underlying the link between tau and cognitive decline. In this proposal both local and distant
functional connectivity will be explored to better understand the downstream effects of tau on brain function.
The Braak staging framework, which was originally derived from cross-sectional data, is an essential
component of neuropathological diagnosis of AD. The current proposal will apply a recently developed in vivo
Braak staging approach to longitudinal data for the first time. Findings from the studies described here will be
novel and high impact. Furthermore, the outcomes of this proposal will contribute to efforts to differentiate
normal aging from pathological aging-related trajectories. The accurate identification of individuals with
preclinical AD will be critical to effective delivery and assessment of early intervention approaches.
1

## Key facts

- **NIH application ID:** 9821171
- **Project number:** 5F32AG057107-03
- **Recipient organization:** UNIVERSITY OF CALIFORNIA BERKELEY
- **Principal Investigator:** Theresa M. Harrison
- **Activity code:** F32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $5,621
- **Award type:** 5
- **Project period:** 2017-12-01 → 2020-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9821171

## Citation

> US National Institutes of Health, RePORTER application 9821171, Tracking Tau with In Vivo Braak Staging: Longitudinal Analysis of Tau Pathology and Functional Sequelae in Cognitively Healthy Older Adults (5F32AG057107-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9821171. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*